deferoxamine has been researched along with Acute Kidney Injury in 33 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Acute Kidney Injury: Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to test the primary hypothesis that in patients suffering from shock, treatment with N-acetylcysteine (NAC) plus deferoxamine (DFX) decreases the incidence of acute kidney injury (AKI)." | 9.22 | N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial. ( Dal-Pizzol, F; Damasio, DC; Fraga, CM; Ritter, C; Tomasi, CD; Vuolo, F, 2016) |
| "We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 7.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
| "Treatment with deferoxamine (iron chelator) did not affect WRN." | 5.39 | N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy. ( Brodsky, SV; Hebert, LA; Nadasdy, G; Nadasdy, T; Ozcan, A; Qamri, Z; Rovin, BH; Satoskar, AA; Ware, K, 2013) |
| "The aim was to test the primary hypothesis that in patients suffering from shock, treatment with N-acetylcysteine (NAC) plus deferoxamine (DFX) decreases the incidence of acute kidney injury (AKI)." | 5.22 | N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial. ( Dal-Pizzol, F; Damasio, DC; Fraga, CM; Ritter, C; Tomasi, CD; Vuolo, F, 2016) |
| "We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years." | 5.17 | Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. ( Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013) |
| "We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 3.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
| "Treatment with deferoxamine (iron chelator) did not affect WRN." | 1.39 | N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy. ( Brodsky, SV; Hebert, LA; Nadasdy, G; Nadasdy, T; Ozcan, A; Qamri, Z; Rovin, BH; Satoskar, AA; Ware, K, 2013) |
| "Ischemia/reperfusion injury is a leading cause of acute renal failure triggering an inflammatory response associated with infiltrating macrophages, which determine disease outcome." | 1.38 | Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. ( Hotter, G; Hughes, J; Jung, M; Kluth, DC; Pérez-Ladaga, A; Sola, A; Viñas, JL; Vinuesa, E, 2012) |
| "Glycerol treatment resulted in marked renal oxidative stress and deranged renal functions which significantly improved by trimetazidine and deferoxamine treatments." | 1.32 | Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine. ( Chander, V; Chopra, K; Singh, D, 2003) |
| "A 17-year-old patient with sickle cell-beta thalassemia undergoing treatment with home iron chelation therapy inadvertently received ten times the recommended dose of intravenous deferoxamine." | 1.32 | Acute renal failure following deferoxamine overdose. ( Flynn, JT; Levine, JE; Prasannan, L, 2003) |
| " Iron has been implicated to play an important role in several models of tissue injury, presumably through the generation of hydroxyl radicals via the Haber-Weiss reaction or other highly toxic free radicals." | 1.30 | In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. ( Baliga, M; Baliga, R; Shah, SV; Ueda, N; Zhang, Z, 1998) |
| "In the case of myoglobinuric acute renal failure (ARF), persistence of myoglobin within tubular cells, or sublethal injury sustained at the height of exposure to it, might retard this process." | 1.29 | Myoglobin inhibits proliferation of cultured human proximal tubular (HK-2) cells. ( Iwata, M; Zager, RA, 1996) |
| "These data suggest that acute renal failure induced by paraquat is mainly related to the hydroxyl radicals produced via the iron-catalyzed Haber-Weiss reaction." | 1.28 | Protective effects of antioxidants on paraquat-induced acute renal failure in mice. ( Nagano, N; Nishikori, K; Yagi, M, 1992) |
| " Dosage recommendations for HF and CAVH are given." | 1.28 | Clinical aspects and applications of hemofiltration. ( Weiss, LG, 1989) |
| "Rats treated with gentamicin (G) alone (100 mg/kg, s." | 1.27 | Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. ( Shah, SV; Walker, PD, 1988) |
| "Glycerol injection was also associated with significant lipid peroxidation, measured as renal malondialdehyde content." | 1.27 | Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. ( Paller, MS, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (21.21) | 18.7374 |
| 1990's | 8 (24.24) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, X | 1 |
| Zhang, X | 1 |
| Liu, LC | 1 |
| Zhang, S | 1 |
| Pelger, CB | 1 |
| Lughmani, HY | 1 |
| Haller, ST | 1 |
| Gunning, WT | 1 |
| Cooper, CJ | 1 |
| Gong, R | 1 |
| Dworkin, LD | 1 |
| Gupta, R | 1 |
| Adedoyin, O | 1 |
| Boddu, R | 1 |
| Traylor, A | 1 |
| Lever, JM | 1 |
| Bolisetty, S | 1 |
| George, JF | 1 |
| Agarwal, A | 1 |
| Umemura, M | 1 |
| Kim, JH | 1 |
| Aoyama, H | 1 |
| Hoshino, Y | 1 |
| Fukumura, H | 1 |
| Nakakaji, R | 1 |
| Sato, I | 1 |
| Ohtake, M | 1 |
| Akimoto, T | 1 |
| Narikawa, M | 1 |
| Tanaka, R | 1 |
| Fujita, T | 1 |
| Yokoyama, U | 1 |
| Taguri, M | 1 |
| Okumura, S | 1 |
| Sato, M | 1 |
| Eguchi, H | 1 |
| Ishikawa, Y | 1 |
| Ware, K | 1 |
| Qamri, Z | 1 |
| Ozcan, A | 1 |
| Satoskar, AA | 1 |
| Nadasdy, G | 1 |
| Rovin, BH | 1 |
| Hebert, LA | 1 |
| Nadasdy, T | 1 |
| Brodsky, SV | 1 |
| Vichinsky, E | 1 |
| Torres, M | 1 |
| Minniti, CP | 1 |
| Barrette, S | 1 |
| Habr, D | 1 |
| Zhang, Y | 1 |
| Files, B | 1 |
| Akiyama, M | 1 |
| Kaneko, Y | 1 |
| Hanaoka, H | 1 |
| Kuwana, M | 1 |
| Takeuchi, T | 1 |
| Fraga, CM | 3 |
| Tomasi, CD | 2 |
| Damasio, DC | 1 |
| Vuolo, F | 2 |
| Ritter, C | 3 |
| Dal-Pizzol, F | 3 |
| Hirschberg, R | 1 |
| Bennett, W | 1 |
| Scheinman, J | 1 |
| Coppo, R | 1 |
| Ponticelli, C | 1 |
| Kontoghiorghes, GJ | 1 |
| Petronilho, F | 2 |
| Constantino, L | 1 |
| de Souza, B | 1 |
| Reinke, A | 1 |
| Martins, MR | 1 |
| Biff, D | 1 |
| Topanotti, MF | 1 |
| Felisberto, F | 1 |
| Vlahakos, D | 1 |
| Arkadopoulos, N | 1 |
| Kostopanagiotou, G | 1 |
| Siasiakou, S | 1 |
| Kaklamanis, L | 1 |
| Degiannis, D | 1 |
| Demonakou, M | 1 |
| Smyrniotis, V | 1 |
| Jung, M | 1 |
| Sola, A | 1 |
| Hughes, J | 1 |
| Kluth, DC | 1 |
| Vinuesa, E | 1 |
| Viñas, JL | 1 |
| Pérez-Ladaga, A | 1 |
| Hotter, G | 1 |
| Chander, V | 1 |
| Singh, D | 1 |
| Chopra, K | 1 |
| Prasannan, L | 1 |
| Flynn, JT | 1 |
| Levine, JE | 1 |
| Li Volti, S | 1 |
| Maccarone, C | 1 |
| Li Volti, G | 1 |
| Romeo, MA | 1 |
| Clajus, C | 1 |
| Becker, JU | 1 |
| Stichtenoth, DO | 1 |
| Wortmann, J | 1 |
| Schwarz, A | 1 |
| Kielstein, JT | 1 |
| Erasmus, RT | 1 |
| Kusnir, J | 1 |
| Stevenson, WC | 1 |
| Lobo, P | 1 |
| Herman, MM | 1 |
| Wills, MR | 1 |
| Savory, J | 1 |
| Iwata, M | 1 |
| Zager, RA | 4 |
| Baliga, R | 1 |
| Zhang, Z | 1 |
| Baliga, M | 1 |
| Ueda, N | 1 |
| Shah, SV | 3 |
| Chatterjee, PK | 1 |
| Cuzzocrea, S | 1 |
| Brown, PA | 1 |
| Zacharowski, K | 1 |
| Stewart, KN | 1 |
| Mota-Filipe, H | 1 |
| Thiemermann, C | 1 |
| Batey, R | 1 |
| Scott, J | 1 |
| Jain, S | 1 |
| Sherlock, S | 1 |
| Foerder, CA | 1 |
| Nagano, N | 1 |
| Yagi, M | 1 |
| Nishikori, K | 1 |
| Walker, PD | 2 |
| Weiss, LG | 1 |
| Boyce, NW | 1 |
| Holdsworth, SR | 1 |
| Paller, MS | 1 |
| Tejero Lamarca, J | 1 |
| Yangüela Terroba, J | 1 |
| Diáz-Flores, L | 1 |
| Pannacciulli, I | 1 |
| Paravidino, GF | 1 |
| Siccardi, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure[NCT00870883] | Phase 2 | 81 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations[NCT04333550] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2020-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Acute Kidney Injury
| Article | Year |
|---|---|
Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review.
Topics: Acute Kidney Injury; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Deferoxamine; D | 2015 |
3 trials available for deferoxamine and Acute Kidney Injury
| Article | Year |
|---|---|
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therap | 2013 |
N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial.
Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aged; Critical Illness; Deferoxamine; Double-Blind Metho | 2016 |
The effects of N-acetylcysteine and deferoxamine on plasma cytokine and oxidative damage parameters in critically ill patients with prolonged hypotension: a randomized controlled trial.
Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aged; Antioxidants; Critical Illness; Deferoxamine; Doub | 2012 |
29 other studies available for deferoxamine and Acute Kidney Injury
| Article | Year |
|---|---|
Hemopexin accumulates in kidneys and worsens acute kidney injury by causing hemoglobin deposition and exacerbation of iron toxicity in proximal tubules.
Topics: Acute Kidney Injury; Animals; Cisplatin; Deferoxamine; Hemoglobins; Hemopexin; Iron; Kidney; Kidney | 2022 |
Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells.
Topics: Acetylcysteine; Acute Kidney Injury; Animals; Antioxidants; Carbolines; Cell Death; Cell Line; Cyclo | 2018 |
The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Topics: Acute Kidney Injury; Animals; Antidotes; Antineoplastic Agents; Chelating Agents; Chemical and Drug | 2017 |
N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Animals; Creatinine; Deferoxamine; Erythrocytes; Male; Nephrect | 2013 |
Acute kidney injury due to deferoxamine in a renal transplant patient.
Topics: Acute Kidney Injury; Benzoates; Creatinine; Deferasirox; Deferoxamine; Humans; Kidney Transplantatio | 2008 |
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; | 2008 |
Efficacy of the combination of N-acetylcysteine and desferrioxamine in the prevention and treatment of gentamicin-induced acute renal failure in male Wistar rats.
Topics: Acetylcysteine; Acute Kidney Injury; Animals; Deferoxamine; Drug Therapy, Combination; Free Radical | 2009 |
Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs.
Topics: Acute Disease; Acute Kidney Injury; Animals; Apoptosis; Deferoxamine; Female; Interleukin-6; Ischemi | 2012 |
Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2.
Topics: Acute Kidney Injury; Adoptive Transfer; Animals; Blood Urea Nitrogen; Cell Survival; Deferoxamine; D | 2012 |
Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine.
Topics: Acute Kidney Injury; Animals; Deferoxamine; Disease Models, Animal; Glycerol; Iron Chelating Agents; | 2003 |
Acute renal failure following deferoxamine overdose.
Topics: Acute Kidney Injury; Adolescent; Anemia, Sickle Cell; beta-Thalassemia; Deferoxamine; Drug Overdose; | 2003 |
Acute renal failure following deferoxamine overdose.
Topics: Acute Kidney Injury; Adolescent; Adult; beta-Thalassemia; Deferoxamine; Drug Overdose; Female; Human | 2003 |
Acute kidney injury due to deferoxamine in a renal transplant patient.
Topics: Acute Kidney Injury; Anemia, Hemolytic, Autoimmune; Anti-Glomerular Basement Membrane Disease; Defer | 2008 |
Hyperaluminemia associated with liver transplantation and acute renal failure.
Topics: Acute Kidney Injury; Albumins; Aluminum; Ammonia; Antidotes; Chelating Agents; Coma; Deferoxamine; D | 1995 |
Myoglobin inhibits proliferation of cultured human proximal tubular (HK-2) cells.
Topics: Acute Kidney Injury; Bromodeoxyuridine; Cell Death; Cell Division; Cells, Cultured; Cytotoxins; Defe | 1996 |
In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity.
Topics: Acute Kidney Injury; Animals; Antidotes; Antineoplastic Agents; Blood Urea Nitrogen; Cell Death; Che | 1998 |
Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat.
Topics: Acute Kidney Injury; Animals; Cell Membrane Permeability; Cell Separation; Cells, Cultured; Chelatin | 2000 |
Acute renal insufficiency occurring during intravenous desferrioxamine therapy.
Topics: Acute Kidney Injury; Adolescent; Deferoxamine; Hemosiderosis; Humans; Injections, Intravenous; Male; | 1979 |
Effects of inorganic iron and myoglobin on in vitro proximal tubular lipid peroxidation and cytotoxicity.
Topics: Acute Kidney Injury; Animals; Benzoates; Benzoic Acid; Deferoxamine; Hydroxides; Hydroxyl Radical; I | 1992 |
Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications.
Topics: Acute Kidney Injury; Animals; Deferoxamine; Drug Therapy, Combination; Hydrogen Peroxide; Hydroxides | 1992 |
Protective effects of antioxidants on paraquat-induced acute renal failure in mice.
Topics: Acute Kidney Injury; Animals; Antioxidants; Blood Urea Nitrogen; Creatinine; Deferoxamine; Electroly | 1992 |
Myoglobin depletes renal adenine nucleotide pools in the presence and absence of shock.
Topics: Acute Kidney Injury; Adenine Nucleotides; Animals; Benzoates; Benzoic Acid; Deferoxamine; Female; He | 1991 |
Reactive oxygen metabolites in endotoxin-induced acute renal failure in rats.
Topics: Acute Kidney Injury; Animals; Deferoxamine; Endotoxins; Free Radical Scavengers; Hydrogen Peroxide; | 1990 |
Clinical aspects and applications of hemofiltration.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Aluminum; Bone and Bones; Calcium-B | 1989 |
Hydroxyl radical mediation of immune renal injury by desferrioxamine.
Topics: Acute Kidney Injury; Animals; Antibodies; Basement Membrane; Deferoxamine; Dose-Response Relationshi | 1986 |
Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats.
Topics: Acute Kidney Injury; Animals; Benzoates; Benzoic Acid; Chelating Agents; Deferoxamine; Dimethyl Sulf | 1988 |
Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity.
Topics: Acute Kidney Injury; Animals; Deferoxamine; Disease Models, Animal; Glycerol; Hemoglobins; Iron; Kid | 1988 |
[Nocturanl paroxysmal hemoglobinuria. II. Renal insufficiency in the course of the same (clinical, histological and ultramicroscopic study of the renal pathology and of its development after desferrioxamine therapy)].
Topics: Acute Kidney Injury; Biopsy; Deferoxamine; Female; Hemoglobinuria, Paroxysmal; Humans; Injections, I | 1973 |
[The desferrioxamine test in patients with kidney diseases].
Topics: Acute Kidney Injury; Deferoxamine; Humans; Iron; Kidney Diseases | 1971 |